Skye Bioscience, an American biopharmaceutical company has been involved in the development of proprietary and synthetic cannabinoid-based molecules. The company has been targeting diseases such as glaucoma along with other diseases that current showcase significant unmet needs. The company announced on Oct 21 of the sponsored research presented by researchers from University of Mississippi.
The California-based company sponsored two research studies were presented at this year’s American Association of Pharmaceutical Scientists Meeting (AAPS) PharmSci 360. The event held from October 17 to 20, 2021 in Philadelphia, Pennsylvania witnessed two poster presentations. The first research revolved around the phenomenon of several nanoemulsion formulations of THCVHS. It assessed the intraocular pressure (IOP) and the lowering effects of the above-mentioned phenomenon. Whereas the second study evaluated the effects on IOP of parallel administration of THCVHS, and other IOP lowering drugs.
AAPS acceptance of the SBI-100 highlights the research quality and encourages drug candidate to human trials. Punit Dhillon, CEO and Chair said that the research on THCVHS nanoemulsion via ocular delivery effectively portrays the delivery of THC into the eye reducing IOP. Dhillon added that the co-administration of THCVHS with the existing therapies also advertises the potential of the drug to be used in combination.